Theradaptive Initiates RESTORE Study for Dental Innovations

Theradaptive, Inc., a breakthrough biotechnology firm specialising in tissue regeneration, has commenced the RESTORE Feasibility Study to explore the potential of OsteoAdapt™ DE in promoting bone growth for dental reconstruction. This innovative study marks a significant milestone in dental therapeutics, promising to enhance bone regeneration and widely improving surgical outcomes. 

Located in Frederick, Maryland, Theradaptive is at the forefront of developing targeted protein therapeutics. Their latest product, OsteoAdapt DE, uses the advanced AMP2™ technology to improve bone regeneration processes actively. Traditionally, clinicians rely on materials that may slow healing in alveolar ridge augmentation. OsteoAdapt DE stands out with its osteoinductive properties, minimising residual materials and expediting recovery time. The RESTORE study, led by Dr. Gal Avishai at Israel’s Rabin Medical Centre, will compare this new technology with standard grafting techniques. The secure backing by AFIRM and the Defence Health Agency underscores its potential military applications, particularly for battlefield injuries affecting the jaw and face.